COVID-19 Serology Assays:
To test or not to test?
We look forward to having you join us for this informative webinar event presented by Patrice Hugo, Ph.D.
About This Event
Over the last 6 months, we have all been severely impacted by the COVID-19 pandemic around the world. An unprecedented global effort has taken place to contain and hopefully reduce the impact of COVID-19 on everyone’s lives. Healthcare professionals have been at the frontline of this initiative with the support of public and private sectors. Academic, biopharmaceutical and diagnostic research has increased our knowledge of the SARS-CoV-2 virus and the physiopathology of the COVID-19 infection. In response, Public Health and Regulatory Authorities, policy makers and governments are rapidly adapting to mitigate the risk of COVID-19 spread in the population. In this context, In Vitro Diagnostic (IVD) device manufacturers have quickly produced serology tests detecting the presence of antibodies to SARS-COV-2 virus. Utilizing such tests as the ultimate sentinel to make decisions to cope with and react to the COVID-19 pandemic is being considered. But can it be that simple?
During this webinar the following topics will be covered by Dr. Hugo:
- Overview of the immune response to COVID-19 infection
- Diagnostic testing concepts
- Serology tests to estimate COVID-19 exposure in the general population
- How Serology tests can be the basis of “Certificate of Immunity”
- Serology tests and laboratory solutions to support clinical trials
This webinar will include a Q&A session.
Immunology; Chief Scientific Officer
Dr. Patrice Hugo obtained his Ph.D. in Experimental Medicine/Immunology at McGill University and completed 5 years of post-doctoral fellowships in Immunology at the Walter Elisa Hall Institute in Australia, and at the Howard Hughes Medical Institute in Denver, Colorado. He then became a Principal Investigator leading the T-lymphocyte Unit at the Montreal Clinical Research Institute with academic appointments at McGill University and Montreal University. Throughout his academic work, Dr. Hugo focused on T-lymphocyte differentiation, self-tolerance induction, and leukemogenesis. He worked at PROCREA BioSciences and Caprion as Chief Scientific Officer and Executive Vice President R&D, respectively. Dr. Hugo was assigned as Chief Scientific Officer at Clearstone Central Laboratories later acquired by LabCorp and became Associate Vice President and Chief Scientist at LabCorp/Covance Central Laboratories Division. Dr. Patrice Hugo joined Q2 Solutions as Chief Scientific Officer where he currently leads the global scientific strategy and is responsible for the medical affairs and scientific activities of the Central Laboratories, and the Specialty Testing Centers of Excellence worldwide including Expression Analysis Genomics, Vaccine, Biomarkers and BioAnalytical/ADME laboratories. Dr. Hugo has more than 75 peer-reviewed scientific publications. He also played an active role in a number of industry organizations, including being a member of the Board of Directors for Personalized Medicine Partnership for Cancer in Quebec, and the Steering Committee for the Biomarker Factory. He is also a member of the American Society of Clinical Oncology (ASCO) and the Society for Immunotherapy of Cancer (SITC).